Prognostic value of echocardiography and ECG in heart failure with preserved ejection fraction
| Autor: | K. Cenkerova, O. Jurkovicova, J. Dubrava, J. Kaluzay, V. Pokorna |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Economics and Econometrics medicine.medical_specialty Slovakia Systole Systolic function 030204 cardiovascular system & hematology QT interval 03 medical and health sciences Electrocardiography 0302 clinical medicine Internal medicine Outcome Assessment Health Care Materials Chemistry Media Technology medicine Humans 030212 general & internal medicine Prospective Studies Aged Aged 80 and over Heart Failure Ejection fraction business.industry Forestry Stroke Volume Middle Aged medicine.disease Prognosis Hospitalization Echocardiography Heart failure Cardiology Female business Heart failure with preserved ejection fraction Follow-Up Studies |
| Zdroj: | Bratislavske lekarske listy. 117(7) |
| ISSN: | 0006-9248 |
| Popis: | Objective The aim of this study was to evaluate characteristics of patients with heart failure (HF) with preserved ejection fraction (HFPEF) and to assess prognostic predictors in 2-year follow-up. Methods We included prospectively 109 patients admitted to the internal department for HF, grouped into HFPEF (EF>40 %, n = 63) and HF with reduced EF (HFREF) (EF≤40 %, n=46). Preserved right ventricular systolic function (PRV) was defined as the peak systolic tricuspid annular velocity (S') >10.8 cm/s. Results HFPEF and HFREF patients had non-significantly different 2-year all-cause and CV mortality (28.6 % vs 37.0 %, 17.5 % vs 21.7 %). Patients with HFPEF and PRV vs dysfunctional RV had a better survival (76.6 % vs 56.3 %, p=0.045). In HFPEF, the patients who survived had a trend to better S' (13.6±3.1 cm/s vs 11.9±3.4 cm/s, p=0.055), shorter QTc (427±42ms vs 454±42ms, p=0.058), and all-cause mortality was lowered only by anticoagulants (12.0 % vs 39.5 %, p=0.02). QTc interval and PRV emerged as predictors of all-cause mortality (HR 1.7 per 40 ms change, 95 % CI 1.1-2.6, p = 0.02, HR 0.38, 95 % CI 0.15-0.93, p=0.03). Conclusions In HFPEF, we observed a trend to lower all-cause and CV mortality compared to HFREF and anticoagulants were the only therapy that significantly lowered mortality. PRV and QTc interval emerged as independent predictors of survival (Tab. 6, Fig. 2, Ref. 26). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|